Abstract

Dynamin-like GTPase proteins, including myxoma (Mx) and guanylate-binding proteins (GBPs), are among the many interferon stimulated genes induced following viral infections. While studies report that human (h)GBPs inhibit different viruses in vitro, few have convincingly demonstrated that mouse (m)GBPs mediate antiviral activity, although mGBP-deficient mice have been used extensively to define their importance in immunity to diverse intracellular bacteria and protozoa. Herein, we demonstrate that individual (overexpression) or collective (knockout (KO) mice) mGBPs of the chromosome 3 cluster (mGBPchr3) do not inhibit replication of five viruses from different virus families in vitro, nor do we observe differences in virus titres recovered from wild type versus mGBPchr3 KO mice after infection with three of these viruses (influenza A virus, herpes simplex virus type 1 or lymphocytic choriomeningitis virus). These data indicate that mGBPchr3 do not appear to be a major component of cell-intrinsic antiviral immunity against the diverse viruses tested in our studies.

Mouse guanylate binding proteins of the chromosome 3 cluster (mGBPchr3) do not mediate potent antiviral activity against different human or mouse viruses in vitro and in vivo.

Details

Title
Mouse guanylate-binding proteins of the chromosome 3 cluster do not mediate antiviral activity in vitro or in mouse models of infection
Author
Tessema, Melkamu B. 1   VIAFID ORCID Logo  ; Feng, Shouya 2   VIAFID ORCID Logo  ; Enosi Tuipulotu, Daniel 3   VIAFID ORCID Logo  ; Farrukee, Rubaiyea 4 ; Ngo, Chinh 5 ; Gago da Graça, Catarina 4 ; Yamomoto, Masahiro 6   VIAFID ORCID Logo  ; Utzschneider, Daniel T. 4   VIAFID ORCID Logo  ; Brooks, Andrew G. 4   VIAFID ORCID Logo  ; Londrigan, Sarah L. 4 ; Man, Si Ming 5   VIAFID ORCID Logo  ; Reading, Patrick C. 1   VIAFID ORCID Logo 

 University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Department of Microbiology and Immunology, Victoria, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); at The Peter Doherty Institute for Infection and Immunity, WHO Collaborating Centre for Reference and Research on Influenza, Victorian Infectious Diseases Reference Laboratory, Victoria, Australia (GRID:grid.433799.3) (ISNI:0000 0004 0637 4986) 
 The Australian National University, Division of Immunology and Infectious Disease, The John Curtin School of Medical Research, Canberra, Australia (GRID:grid.1001.0) (ISNI:0000 0001 2180 7477); The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia (GRID:grid.1042.7) (ISNI:0000 0004 0432 4889) 
 The Australian National University, Division of Immunology and Infectious Disease, The John Curtin School of Medical Research, Canberra, Australia (GRID:grid.1001.0) (ISNI:0000 0001 2180 7477); University of Technology Sydney, School of Life Sciences, Faculty of Science, Ultimo, Australia (GRID:grid.117476.2) (ISNI:0000 0004 1936 7611) 
 University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Department of Microbiology and Immunology, Victoria, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X) 
 The Australian National University, Division of Immunology and Infectious Disease, The John Curtin School of Medical Research, Canberra, Australia (GRID:grid.1001.0) (ISNI:0000 0001 2180 7477) 
 Osaka University, Department of Immunoparasitology, Research Institute for Microbial Diseases, Osaka, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971) 
Pages
1050
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
23993642
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3096712507
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.